ABBIE SIEBENHAAR: Open Payments
NPI 1295003234 · SALT LAKE CITY, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,277 in 81 payments from 17 companies in 2025. Trend: 2023 $942 · 2024 $1,433 · 2025 $1,277
Food & beverage: $1,277
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $303 |
| Janssen Biotech, Inc. | 22 | $298 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $99 |
| Celltrion USA Inc. | 4 | $75 |
| Ipsen Biopharmaceuticals, Inc | 3 | $62 |
| Regeneron Healthcare Solutions, Inc. | 3 | $59 |
| Gilead Sciences, Inc. | 3 | $57 |
| ORPHALAN INC | 2 | $55 |
| GENZYME CORPORATION | 3 | $51 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $50 |
Products named: TREMFYA, RINVOQ, DUPIXENT, VEGZELMA, SKYRIZI, IQIRVO, CUVRIOR, XIFAXAN.
Industry payments across UT — which companies pay providers there.
